 Catalyst Biosciences is highly committed to its cash distribution plan to shareholders of up to 65 million in the near future, with only a 58 million market capitalization. If the proxy contest is cleared up between Catalyst and JDS1 and goes in favor of the executives of Catalyst, shareholders should expect an initial cash distribution of 45 million. 